Ruboxistaurin (1 mg/kg; 8 weeks) markedly reduces GEC apoptosis as well as swiprosin-1 upregulation, and ameliorates renal glomerular injury in the diabetic mice. Ruboxistaurin also potently attenuates the expression of PARP, cleaved-caspase9, cleaved-caspase3, and the Bax/Bcl-2 ratio, in diabetic mice[3]. Ruboxistaurin (0.1, 1.0, or 10.0 mg/kg; p.o.) dramatically reduces the number of leukocytes trapped in the retinal microcirculation of diabetic rats[4].
| Animal Model: | Rats[4] |
| Dosage: | 0.1, 1.0, or 10.0 mg/kg |
| Administration: | P.o. |
| Result: | Dramatically reduced the number of leukocytes trapped in the retinal microcirculation of diabetic rats. |
